MediPharm Labs Stock (TSXV: LABS) (OTC: MLCPF) - Investor Dashboard


➔ MediPharm Labs
TSX Venture Exchange: LABS
OTC Ticker: MLCPF
Sector: Industrial
Industry: Pharmaceutical
Country: Canada
Employees: 45
Established: 2015
CEO: Patrick McCutcheon

MediPharm Labs –  Management Team


Patrick McCutcheon, President and CEO

Before founding MediPharm Labs, Pat enjoyed a 15-year career in the pharmaceutical industry in top sales roles, successfully launching a wide range of medical products. He most recently worked at Jansen Pharmaceuticals (Johnson & Johnson) where he led the Hospital Division for Renal and Mental Health products. Pat’s foresight in creating a business that focuses on advanced cannabis concentrates bodes well for medical research, investors and consumers alike. Pat holds an Honors Bachelor of Science degree in biology from the University of Western Ontario.

Chris Hobbs, Chief Financial Officer

Over the past 18 years, Chris has acted as Chief Financial Officer for several private and public companies operating in the resource, health sciences, and technology sectors. Chris is a member of the Chartered Accountants of Ontario and holds a Bachelor of Business Administration from the Schulich School of Business at York University.

David Mayers, Chief Operating Officer

David has more than 25 years of pharmaceutical leadership experience. He began his career as a chemist at SmithKline Beecham (now GlaxoSmithKline). He most recently served as the COO of Impopharma Inc. David earned his Hons. BSc in biological science from the University of Guelph and his MBA from the Rotman School of Business at the University of Toronto.

Sybil Taylor, Chief Marketing Officer

A 25-year marketing veteran, Sybil has brought premium consumer brands to life by developing innovative customer-focused marketing strategies. She launched Steam Whistle Pilsner in 2000 as a pioneering upstart and helped it grow to the largest craft beer brand in Canada. As CMO at Nuuvera Canada, Sybil was a senior contributor to this Canadian Cannabis start-up via strategic planning and brand development for medical and recreational brands. Sybil has been part of senior teams in two of Canada’s Best Managed Companies, and through CSR initiatives, she has brought numerous awards and public profile to her managed brands.

Keith Strachan, VP Business Development

Keith is a Supply Chain Management expert having held various procurement positions in different Ministries/Agencies including correctional services, policing, transportation and healthcare. He has operated a business development consulting practice, specializing in Public Sector RFP and government contracts, compliance for government licensing and local planning. Keith has a passion for entrepreneurship with ownership in several companies in the hospitality industry.

Anuja Siwakoti, Director of Global Regulatory and Scientific Affairs

Anuja has eight years of experience in research and work in the Canadian cannabis industry. In her previous role as a Senior Quality/Regulatory Consultant at Cannabis Compliance Inc., she helped more than 50 clients navigate the regulatory landscape. She also has previous experience working in the quality department at Aphria. Anuja earned her master’s degree in the medical sciences program at McMaster University.

Dr. Chris Talpas, Director of Quality Control & Assurance

Chris has 24 years of experience in the biopharmaceutical field, having been involved in all aspects of development from bench-top to commercial manufacture. After completing his BSc. and Doctorate degrees in Biochemistry, he joined Hemosol as a research scientist and then transitioned into the Process Development group where he worked on scaling up the manufacturing process to support clinical manufacturing of a hemoglobin-based blood substitute. Thereafter, he managed the clinical manufacturing plant. An expert in Chromatography, Dr. Talpas comes to MediPharm with a wealth of expertise in the qualification and validation of complex processes and equipment, as well as the development and maintenance of quality systems, having just served as the Director of Manufacturing Sciences at Therapure Biopharma.

Ahmed Shehata, General Counsel

Ahmed comes to MediPharm after having spent the previous 10 years working in the Business Law Group in the Bay Street office of one of the world’s largest law firms where his practice consisted of securities law, mergers and acquisitions, corporate finance and general corporate and commercial law. Ahmed has acted as external counsel for numerous cannabis companies and has been involved in a legal advisory role in the going public transactions of cannabis companies as well as companies in several other industries. He holds a Juris Doctor Law Degree from Osgoode Hall Law School and a Bachelor of Commerce Honours Degree from the Queen’s University School of Business.

Significant Insider Ownership


Patrick McCutcheon, CEO
8.06 million shares

Keith Strachan, VP, Business Development
6.34 million shares

Ahmed Shehata, General Counsel
3.17 million shares


Visit MediPharm Labs
at www.medipharmlabs.com

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Medipharm Labs, Inc. is a client of NCV Media, LLC. Read our full disclaimer.